Conference Dates
June 12 – 17, 2022
Abstract
Virus-like particles (VLPs) constitute a promising approach for recombinant vaccine development. They are robust, safe, versatile and high immunogenic supra-molecular structures that closely mimic the native conformation of the viruses without carrying its genetic material. HIV-1 Gag VLPs share similar characteristics with wild type Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) virus, making them a suitable platform to express the Spike membrane protein to generate a potential vaccine candidate for COVID-19. This work proposes a methodology for the generation of SARS-CoV-2 VLPs by its co-expression with HIV-1 Gag protein by transient transfection of HEK 293 cultures. We first evaluated the cellular co-expression of SARS-CoV-2 Spike glycoprotein with HIV-1 Gag: confocal microscopy analysis showed that after its expression, native envelope Spike glycoprotein travels to the plasmatic membrane of the HEK 293 producer cells, where it co-localizes with Gag::eGFP (Figure 1.A,B) and Spike-functionalized VLPs (S-VLP) generation occurs.
Please click Download on the upper right corner to see the full abstract.
Recommended Citation
Amau Boix-Besora, Elianet Lorenzo, Jesus Lavado-Garcia, Francesc Gòdia, and Laura Cervera, "Optimization, production, purification and characterization of HIV-1 Gag VLPs functionalized with SARS-CoV-2 Spike glycoprotein" in "Vaccine Technology VIII", Tarit Mukhopadhyay, Merck Research Laboratories, USA; Charles Lutsch, Sanofi Pasteur, France; Linda Hwee-Lin Lua, University of Queensland, Australia; Francesc Godia, Universitat Autònoma de Barcelona, Spain Eds, ECI Symposium Series, (2022). https://dc.engconfintl.org/vaccine_viii/121
